{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:44:47Z","timestamp":1793123087522,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Broadly neutralizing antibodies (bNAbs) represent a novel approach to HIV treatment, prevention, and cure strategies. As research advances, the clinical application of bNAbs continues to evolve. This review explores the potential role of bNAbs in HIV management, addressing their mechanisms of action, current limitations, and future directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent studies have demonstrated that bNAbs can effectively neutralize a broad range of HIV strains by targeting conserved epitopes on the viral envelope. Clinical trials have shown that bNAb combinations can maintain viral supression in the absence of antiretroviral therapy (ART), though pre-existing resistance remains a major challenge. Strategies such as Fc engineering and alternative delivery mechanisms (e.g., AAV, mRNA, DNA) are being explored to enhance bNAb efficacy and durability. Despite promising data, bNAbs have not yet demonstrated superior effectiveness compared to existing ART or pre-exposure prophylaxis (PrEP) options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>While bNAbs offer exciting possibilities for long-acting HIV therapy, their widespread use is limited by logistical challenges, high production costs, and pre-existing viral resistance. The future of bNAbs may lie in combination strategies with small-molecule antiretrovirals in maintenance strategies, genetic delivery systems, and vaccine-based approaches to induce endogenous bNAb production. Further research is needed to refine these strategies and determine the optimal role of bNAbs in HIV care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11904-025-00744-1","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:17:41Z","timestamp":1748323061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Future of bNAbs in HIV Treatment"],"prefix":"10.1007","volume":"22","author":[{"given":"Pablo","family":"Tebas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"744_CR1","unstructured":"Organization WH. Global Health Observatory: HIV\/AIDS Data. 2024 (https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids)"},{"issue":"12","key":"744_CR2","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-Acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1904398.","journal-title":"N Engl J Med"},{"issue":"19","key":"744_CR3","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer S, DeJesus E, Stellbrink H-J, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 infection. N Engl J Med. 2022;386(19):1793\u2013803. https:\/\/doi.org\/10.1056\/NEJMoa2115542.","journal-title":"N Engl J Med"},{"key":"744_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3389\/fpubh.2021.690017","volume":"9","author":"DA Spencer","year":"2021","unstructured":"Spencer DA, Shapiro MB, Haigwood NL, Hessell AJ. Advancing HIV broadly neutralizing antibodies: from discovery to the clinic. Front Public Health. 2021;9:610.","journal-title":"Front Public Health"},{"issue":"11","key":"744_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41577-023-00858-w","volume":"23","author":"DR Burton","year":"2023","unstructured":"Burton DR. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nat Rev Immunol. 2023;23(11):720\u201334. https:\/\/doi.org\/10.1038\/s41577-023-00858-w.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"744_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/rmv.1980050306","volume":"5","author":"NJ Dimmock","year":"1995","unstructured":"Dimmock NJ. Update on the neutralization of animal viruses. Rev Med Virol. 1995;5(3):165\u201379. https:\/\/doi.org\/10.1002\/rmv.1980050306. (In English).","journal-title":"Rev Med Virol"},{"key":"744_CR7","doi-asserted-by":"publisher","unstructured":"Klasse PJ. Neutralization of virus infectivity by antibodies: old problems in new perspectives. Adv Biol. 2014;2014. https:\/\/doi.org\/10.1155\/2014\/157895.","DOI":"10.1155\/2014\/157895"},{"issue":"1","key":"744_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12977-018-0453-y","volume":"15","author":"LE McCoy","year":"2018","unstructured":"McCoy LE. The expanding array of HIV broadly neutralizing antibodies. Retrovirology. 2018;15(1):70. https:\/\/doi.org\/10.1186\/s12977-018-0453-y. (In eng).","journal-title":"Retrovirology"},{"issue":"2","key":"744_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/08830185.2021.1960986","volume":"42","author":"D Kandari","year":"2023","unstructured":"Kandari D, Bhatnagar R. Antibody engineering and its therapeutic applications. Int Rev Immunol. 2023;42(2):156\u201383.","journal-title":"Int Rev Immunol"},{"issue":"6","key":"744_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382\u201393. https:\/\/doi.org\/10.1038\/s41577-021-00542-x.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"744_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","volume":"35","author":"S Ko","year":"2021","unstructured":"Ko S, Jo M, Jung ST. Recent achievements and challenges in prolonging the serum Half-Lives of therapeutic IgG. Antibodies Through Fc Eng BioDrugs. 2021;35(2):147\u201357. https:\/\/doi.org\/10.1007\/s40259-021-00471-0. (In eng).","journal-title":"Antibodies Through Fc Eng BioDrugs"},{"key":"744_CR12","doi-asserted-by":"publisher","first-page":"108201","DOI":"10.1016\/j.biotechadv.2023.108201","volume":"67","author":"M Garc\u00eda-Alija","year":"2023","unstructured":"Garc\u00eda-Alija M, van Moer B, Sastre DE, et al. Modulating antibody effector functions by Fc glycoengineering. Biotechnol Adv. 2023;67:108201. https:\/\/doi.org\/10.1016\/j.biotechadv.2023.108201. (In eng).","journal-title":"Biotechnol Adv"},{"key":"744_CR13","doi-asserted-by":"publisher","first-page":"1020003","DOI":"10.3389\/fimmu.2022.1020003","volume":"13","author":"J Kang","year":"2022","unstructured":"Kang J, Sun T, Zhang Y. Immunotherapeutic progress and application of bispecific antibody in cancer. Front Immunol. 2022;13:1020003. https:\/\/doi.org\/10.3389\/fimmu.2022.1020003. (In eng).","journal-title":"Front Immunol"},{"issue":"6310","key":"744_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1126\/science.aag3267","volume":"354","author":"AZ Wec","year":"2016","unstructured":"Wec AZ, Nyakatura EK, Herbert AS, et al. A Trojan horse bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354(6310):350\u20134. https:\/\/doi.org\/10.1126\/science.aag3267. (In eng).","journal-title":"Science"},{"key":"744_CR15","unstructured":"Tsibris A, Zheng YE, Capparelli E et al. A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236. 31th Conference on Retrovirus and Oppotunistic infections. March 3\u20136, 2024. Denver, Colorado, Abstract #1182024."},{"key":"744_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13385","author":"F Koch-Nolte","year":"2024","unstructured":"Koch-Nolte F. Nanobody-based heavy chain antibodies and chimeric antibodies. Immunol Rev. 2024. https:\/\/doi.org\/10.1111\/imr.13385. (In eng).","journal-title":"Immunol Rev"},{"key":"744_CR17","doi-asserted-by":"publisher","unstructured":"Yu T, Zheng F, He W, Muyldermans S, Wen Y. Single domain antibody: development and application in biotechnology and biopharma. Immunol Rev 2024 (In eng). https:\/\/doi.org\/10.1111\/imr.13381","DOI":"10.1111\/imr.13381"},{"issue":"7","key":"744_CR18","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1073\/pnas.0630530100","volume":"100","author":"DD Richman","year":"2003","unstructured":"Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci. 2003;100(7):4144\u20139. https:\/\/www.pnas.org\/doi\/pdf\/10.1073\/pnas.0630530100.","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"744_CR19","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/s41591-021-01503-6","volume":"27","author":"J Blazkova","year":"2021","unstructured":"Blazkova J, Gao F, Marichannegowda MH, et al. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nat Med. 2021;27(11):1893\u20138. https:\/\/doi.org\/10.1038\/s41591-021-01503-6.","journal-title":"Nat Med"},{"issue":"8","key":"744_CR20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/QAD.0000000000003575","volume":"37","author":"P Tebas","year":"2023","unstructured":"Tebas P, Lynn K, Azzoni L, et al. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. AIDS. 2023;37(8):1203\u20137. https:\/\/doi.org\/10.1097\/QAD.0000000000003575.","journal-title":"AIDS"},{"issue":"11","key":"744_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384(11):1003\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2031738.","journal-title":"N Engl J Med"},{"issue":"23","key":"744_CR22","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188\u2013200. https:\/\/doi.org\/10.1056\/NEJMoa2116620. (In eng).","journal-title":"N Engl J Med"},{"issue":"10","key":"744_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","volume":"10","author":"H Montgomery","year":"2022","unstructured":"Montgomery H, Hobbs FR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab\u2013cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Med. 2022;10(10):985\u201396.","journal-title":"Lancet Respiratory Med"},{"key":"744_CR24","first-page":"ofae388","volume-title":"Implementation of an approach to equitable allocation of SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis: experience from a single medical center","author":"KW Hamilton","year":"2024","unstructured":"Hamilton KW, Hua E, Dutcher L, et al. Implementation of an approach to equitable allocation of SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis: experience from a single medical center. Open Forum Infectious Diseases: Oxford University Press US; 2024. p. ofae388."},{"issue":"27","key":"744_CR25","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1011205. (In eng).","journal-title":"N Engl J Med"},{"issue":"5","key":"744_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1108524. (In eng).","journal-title":"N Engl J Med"},{"issue":"10246","key":"744_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0140-6736(20)31065-5","volume":"396","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and Tenofovir Alafenamide vs emtricitabine and Tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(20)31065-5. (In eng).","journal-title":"Lancet"},{"issue":"7","key":"744_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2101016. (In eng).","journal-title":"N Engl J Med"},{"issue":"10337","key":"744_CR29","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/s0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389. https:\/\/doi.org\/10.1016\/s0140-6736(22)00538-4. (In eng).","journal-title":"Lancet"},{"key":"744_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001","author":"LG Bekker","year":"2024","unstructured":"Bekker LG, Das M, Abdool Karim Q, et al. Twice-Yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2407001. (In eng).","journal-title":"N Engl J Med"},{"issue":"7557","key":"744_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487\u201391. https:\/\/doi.org\/10.1038\/nature14411. (In eng).","journal-title":"Nature"},{"issue":"319","key":"744_CR32","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7(319):319ra206. https:\/\/doi.org\/10.1126\/scitranslmed.aad5752. (In eng).","journal-title":"Sci Transl Med"},{"issue":"2","key":"744_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey M, Schoofs T, Gruell H, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185\u201391.","journal-title":"Nat Med"},{"issue":"10","key":"744_CR34","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson KE, Julg B, Tan CS, et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021;27(10):1718\u201324.","journal-title":"Nat Med"},{"issue":"11","key":"744_CR35","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On Y, Gruell H, Schoofs T, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018;24(11):1701\u20137. https:\/\/doi.org\/10.1038\/s41591-018-0186-4. (In eng).","journal-title":"Nat Med"},{"issue":"21","key":"744_CR36","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375(21):2037\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1608243.","journal-title":"N Engl J Med"},{"issue":"7724","key":"744_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479\u201384. https:\/\/doi.org\/10.1038\/s41586-018-0531-2.","journal-title":"Nature"},{"issue":"703","key":"744_CR38","doi-asserted-by":"publisher","first-page":"eadh0004","DOI":"10.1126\/scitranslmed.adh0004","volume":"15","author":"RL Shapiro","year":"2023","unstructured":"Shapiro RL, Ajibola G, Maswabi K, et al. Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Sci Transl Med. 2023;15(703):eadh0004. https:\/\/doi.org\/10.1126\/scitranslmed.adh0004. (In eng).","journal-title":"Sci Transl Med"},{"issue":"7913","key":"744_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller MC, Blazkova J, Justement JS, et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature. 2022;606(7913):375\u201381. https:\/\/doi.org\/10.1038\/s41586-022-04797-9. (In eng).","journal-title":"Nature"},{"key":"744_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03247-5","author":"B Julg","year":"2024","unstructured":"Julg B, Walker-Sperling VEK, Wagh K, et al., et al. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03247-5. In eng.","journal-title":"Nat Med"},{"key":"744_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae486","author":"MH Pahus","year":"2024","unstructured":"Pahus MH, Zheng Y, Olefsky M, et al. Evaluation and Real-world experience of a neutralization susceptibility screening assay for broadly neutralizing Anti\u2013HIV-1 antibodies. J Infect Dis. 2024. https:\/\/doi.org\/10.1093\/infdis\/jiae486.","journal-title":"J Infect Dis"},{"issue":"3","key":"744_CR42","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/s2352-3018(23)00293-x","volume":"11","author":"JJ Eron","year":"2024","unstructured":"Eron JJ, Little SJ, Crofoot G, et al. Safety of teropavimab and Zinlirvimab with Lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV. 2024;11(3):e146\u201355. https:\/\/doi.org\/10.1016\/s2352-3018(23)00293-x. (In eng).","journal-title":"Lancet HIV"},{"key":"744_CR43","unstructured":"Taiwo B, Zheng YE, Rodriguez K et al. Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial. 31th Conference on Retrovirus and Oppotunistic infections. March 3\u20136, 2024. Denver, Colorado, Abstract #1192024."},{"issue":"1","key":"744_CR44","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1038\/s41467-022-34171-2","volume":"13","author":"M Ros\u00e1s-Umbert","year":"2022","unstructured":"Ros\u00e1s-Umbert M, Gunst JD, Pahus MH, et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity. Nat Commun. 2022;13(1):6473. https:\/\/doi.org\/10.1038\/s41467-022-34171-2. (In eng).","journal-title":"Nat Commun"},{"issue":"10","key":"744_CR45","doi-asserted-by":"publisher","first-page":"ofy242","DOI":"10.1093\/ofid\/ofy242","volume":"5","author":"SA Riddler","year":"2018","unstructured":"Riddler SA, Zheng L, Durand CM, et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect Dis. 2018;5(10):ofy242\u2013242. https:\/\/doi.org\/10.1093\/ofid\/ofy242. (In eng).","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"744_CR46","doi-asserted-by":"publisher","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","volume":"10","author":"JH Elliott","year":"2014","unstructured":"Elliott JH, Wightman F, Solomon A, et al. Activation of HIV transcription with short-course Vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014;10(10):e1004473. https:\/\/doi.org\/10.1371\/journal.ppat.1004473.","journal-title":"PLoS Pathog"},{"issue":"5","key":"744_CR47","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/infdis\/jiab487","volume":"225","author":"CL Gay","year":"2022","unstructured":"Gay CL, James KS, Tuyishime M, et al. Stable latent HIV infection and Low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat. J Infect Dis. 2022;225(5):856\u201361. https:\/\/doi.org\/10.1093\/infdis\/jiab487. (In eng).","journal-title":"J Infect Dis"},{"issue":"3","key":"744_CR48","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","volume":"3","author":"H Gruell","year":"2022","unstructured":"Gruell H, Gunst JD, Cohen YZ, et al. Effect of 3BNC117 and Romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe. 2022;3(3):e203\u201314. https:\/\/doi.org\/10.1016\/S2666-5247(21)00239-1.","journal-title":"Lancet Microbe"},{"issue":"11","key":"744_CR49","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst JD, Pahus MH, Ros\u00e1s-Umbert M, et al. Early intervention with 3BNC117 and Romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat Med. 2022;28(11):2424\u201335.","journal-title":"Nat Med"},{"issue":"5","key":"744_CR50","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","volume":"28","author":"JP Casazza","year":"2022","unstructured":"Casazza JP, Cale EM, Narpala S, et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med. 2022;28(5):1022\u201330. https:\/\/doi.org\/10.1038\/s41591-022-01762-x. (In eng).","journal-title":"Nat Med"},{"issue":"12","key":"744_CR51","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August A, Attarwala HZ, Himansu S, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021;27(12):2224\u201333.","journal-title":"Nat Med"},{"issue":"2","key":"744_CR52","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1172\/jci132779","volume":"130","author":"MC Wise","year":"2020","unstructured":"Wise MC, Xu Z, Tello-Ruiz E, et al. In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest. 2020;130(2):827\u201337. https:\/\/doi.org\/10.1172\/jci132779. (In eng).","journal-title":"J Clin Invest"},{"issue":"6623","key":"744_CR53","doi-asserted-by":"publisher","first-page":"eadd6502","DOI":"10.1126\/science.add6502","volume":"378","author":"DJ Leggat","year":"2022","unstructured":"Leggat DJ, Cohen KW, Willis JR, et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science. 2022;378(6623):eadd6502. https:\/\/doi.org\/10.1126\/science.add6502. (In eng).","journal-title":"Science"},{"issue":"6","key":"744_CR54","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","volume":"24","author":"K Xu","year":"2018","unstructured":"Xu K, Acharya P, Kong R, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat Med. 2018;24(6):857\u201367. https:\/\/doi.org\/10.1038\/s41591-018-0042-6. (In eng).","journal-title":"Nat Med"},{"issue":"50","key":"744_CR55","doi-asserted-by":"publisher","first-page":"32066","DOI":"10.1073\/pnas.2020617117","volume":"117","author":"LN Bertagnolli","year":"2020","unstructured":"Bertagnolli LN, Varriale J, Sweet S, et al. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Proc Natl Acad Sci U S A. 2020;117(50):32066\u201377. https:\/\/doi.org\/10.1073\/pnas.2020617117. (In eng).","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00744-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00744-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00744-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:06:11Z","timestamp":1769605571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00744-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00744-1","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"30 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"34"}}